Outlook Therapeutics (OTLK)

• Market cap: $31.7M
• 1 day: 4.88%
• 5 days: -17.03%
• 1 month: 24.86%
• 3 months: -40.41%
• 6 months: -79.83%
• Year to date: -60.27%
• 1 year: -83.3%
• 5 years: -99.44%
• 10 years: -99.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Employees: 17